biguanides has been researched along with Anxiety in 9 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Present study investigated the role of agmatine in ethanol-induced anxiolysis and withdrawal anxiety using elevated plus maze (EPM) test in rats." | 7.76 | Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats. ( Chopde, CT; Kotagale, NR; Patel, MR; Shelkar, GP; Taksande, BG; Ugale, RR, 2010) |
| "Present study investigated the role of agmatine in ethanol-induced anxiolysis and withdrawal anxiety using elevated plus maze (EPM) test in rats." | 3.76 | Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats. ( Chopde, CT; Kotagale, NR; Patel, MR; Shelkar, GP; Taksande, BG; Ugale, RR, 2010) |
| "Neuroanatomical findings revealed that CB1 cannabinoid and 5-HT3 receptors are coexpressed by a subtype of gamma-aminobutyric acid (GABA)ergic interneurons in the prefrontal cortex, hippocampus, and basolateral amygdala, three brain regions that are crucial for the control of anxiety." | 3.75 | Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. ( Aliczki, M; Halasz, J; Haller, J; Mikics, E; Vas, J, 2009) |
| " In this study, we investigated the effect of MCI-225 in anxiety models in comparison with diazepam, ondansetron, maprotiline, imipramine, and trazodone." | 3.71 | The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism. ( Eguchi, J; Inomata, Y; Saito, K, 2001) |
| "The TIME acronym (tissue, infection/inflammation, moisture balance and edge of wound) was first developed more than 10 years ago, by an international group of wound healing experts, to provide a framework for a structured approach to wound bed preparation; a basis for optimising the management of open chronic wounds healing by secondary intention." | 2.48 | Extending the TIME concept: what have we learned in the past 10 years?(*). ( Carville, K; Drake, R; Fletcher, J; Leaper, DJ; Schultz, G; Swanson, T, 2012) |
| " The percentage of patients with good adherence (the proportion of days in which patients took all pills as prescribed in the past 7 days ≥80%) was high (≥90%) in any dosing regimen with no significant difference among the groups." | 1.51 | [Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes]. ( Hayashi, A; Kamei, M; Kubo, T; Okuyama, K; Tokita, S, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Lopes, LT | 1 |
| Canto-de-Souza, L | 1 |
| Baptista-de-Souza, D | 1 |
| de Souza, RR | 1 |
| Nunes-de-Souza, RL | 1 |
| Canto-de-Souza, A | 1 |
| Hayashi, A | 1 |
| Kubo, T | 1 |
| Okuyama, K | 1 |
| Tokita, S | 1 |
| Kamei, M | 1 |
| Kar, SK | 1 |
| Shahi, MK | 1 |
| Roy, P | 1 |
| Mikics, E | 1 |
| Vas, J | 1 |
| Aliczki, M | 1 |
| Halasz, J | 1 |
| Haller, J | 1 |
| Taksande, BG | 1 |
| Kotagale, NR | 1 |
| Patel, MR | 1 |
| Shelkar, GP | 1 |
| Ugale, RR | 1 |
| Chopde, CT | 1 |
| Leaper, DJ | 1 |
| Schultz, G | 1 |
| Carville, K | 1 |
| Fletcher, J | 1 |
| Swanson, T | 1 |
| Drake, R | 1 |
| Talalaenko, AN | 1 |
| Pankrat'ev, DV | 1 |
| Goncharenko, NV | 1 |
| Eguchi, J | 1 |
| Inomata, Y | 1 |
| Saito, K | 1 |
| Hockaday, TD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Study of Quality of Life in Patients With Chronic Leg Wound(s) Treated With Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel[NCT03369756] | 43 participants (Actual) | Interventional | 2018-02-20 | Terminated (stopped due to Terminated due to prolonged subject recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Body consists of Items #1 to #5. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Body Subscore change, Baseline / Week 1 to Week 2 | Body Subscore change, Baseline / Week 1 to Week 3 | Body Subscore change, Baseline / Week 1 to Week 4 | Body Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.76 | -0.93 | -1.19 | -1.17 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Everyday Life consists of Items #Items #11 to #16. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. Generally, the higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Everyday Life Subscore change, Baseline / Week 1 to Week 2 | Everyday Life Subscore change, Baseline / Week 1 to Week 3 | Everyday Life Subscore change, Baseline / Week 1 to Week 4 | Everyday Life Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.58 | -0.82 | -1.11 | -1.00 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. It can be used in clinical and observational studies and in daily practice.~Subscale Psyche consists of Items #Items #6 to #10. Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). The average of the subscale can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Psyche Subscore change, Baseline / Week 1 to Week 2 | Psyche Subscore change, Baseline / Week 1 to Week 3 | Psyche Subscore change, Baseline / Week 1 to Week 4 | Psyche Subscore change, Baseline / Week 1 to End / Week 5 | |
| Prontosan Solution and Gel | -0.77 | -1.04 | -1.24 | -1.26 |
Change in wound size from Baseline/Week 1 to Final/Week 5. The change in the size of a wound will be evaluated using a disposable ruler to directly measure the overall wound dimensions at each scheduled visit to the study site (Weeks 1 and 5). These measurements will be done before any cleaning of the wound and after cleaning the wound (debridement). (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | wound surface area (cm^2) (Mean) | |
|---|---|---|
| Pre-Debridement Wound Size Change (Baseline/Week 1 to Week 5 / End) | Post-Debridement Wound Size Change(Baseline/Week 1 to Final/Week 5) | |
| Prontosan Solution and Gel | -6.6 | -8.2 |
"The Wound-QoL is a tool to measure disease-specific, health-related quality of life of patients with chronic wounds. It consists of 17 items on impairments which is assessed for the previous 7 days and is competed by the patient. It has 3 subscales that can assess Body, Psyche and Everyday Life. These subscales cover items 1 to 16. Item 17 is not part of any of the subscales. The Wound-QoL can be used in clinical and observational studies and in daily practice.~Each individual item is rated on a scale ranging from 0 (not at all) to 4 (very much). A Total or Global score is the average of at least 13 completed questions, regardless of which questions were not completed. The average of each of the 3 subscales can be computed if no more than 1 item of the subscale is missing. The higher values represents more of an impact to the patient for that item." (NCT03369756)
Timeframe: 5 weeks overall (4 weeks of treatment and/or observations followed by a one-day visit at end of study in week 5)
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 / Baseline | Week 2 | Week 3 | Week 4 | Week 5 / End | |
| Prontosan Solution and Gel | 2.41 | 1.74 | 1.51 | 1.25 | 1.30 |
2 reviews available for biguanides and Anxiety
| Article | Year |
|---|---|
Extending the TIME concept: what have we learned in the past 10 years?(*).
Topics: Abbreviations as Topic; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anxiety; Bandages; Bigu | 2012 |
Diabetes mellitus.
Topics: Alcohol Drinking; Anxiety; Biguanides; Blood Glucose; Blood Pressure; Body Weight; Cholesterol, Diet | 1974 |
7 other studies available for biguanides and Anxiety
| Article | Year |
|---|---|
The interplay between 5-HT
Topics: Animals; Anxiety; Behavior, Animal; Biguanides; Male; Mice; Ondansetron; Periaqueductal Gray; Pipera | 2022 |
[Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes].
Topics: Administration, Oral; Adult; Aged; Anxiety; Biguanides; Diabetes Mellitus, Type 2; Dipeptidyl-Peptid | 2019 |
Understanding the anxiety phenomenology in psychotic prodrome: A case report.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Biguanides; Clonazepam; Drug Therapy, Combinatio | 2017 |
Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission.
Topics: Animals; Anxiety; Behavior, Animal; Biguanides; Cannabinoid Receptor Modulators; gamma-Aminobutyric | 2009 |
Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats.
Topics: Agmatine; Animals; Anti-Anxiety Agents; Anxiety; Arginine; Biguanides; Brain; Clonidine; Dose-Respon | 2010 |
Neurochemical characteristics of the ventromedial hypothalamus in mediating the antiaversive effects of anxiolytics in different models of anxiety.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Anti- | 2003 |
The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism.
Topics: Adrenergic Uptake Inhibitors; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Biguanid | 2001 |